Round Table Services Upped By $2.00 Million Its New Mtn Fin (NMFC) Stake; Shorts at Apricus Biosciences (APRI) Raised By 76.52%

June 12, 2017 - By Adrian Erickson

Apricus Biosciences Incorporated (NASDAQ:APRI) had an increase of 76.52% in short interest. APRI’s SI was 1.18 million shares in June as released by FINRA. Its up 76.52% from 669,800 shares previously. With 709,900 avg volume, 2 days are for Apricus Biosciences Incorporated (NASDAQ:APRI)’s short sellers to cover APRI’s short positions. The SI to Apricus Biosciences Incorporated’s float is 20.8%. The stock decreased 3.54% or $0.04 on June 9, reaching $1.09. About shares traded. Apricus Biosciences Inc (NASDAQ:APRI) has declined 71.78% since June 12, 2016 and is downtrending. It has underperformed by 88.48% the S&P500.

Round Table Services Llc increased New Mtn Fin Corp (NMFC) stake by 10.55% reported in 2016Q4 SEC filing. Round Table Services Llc acquired 142,988 shares as New Mtn Fin Corp (NMFC)’s stock declined 2.69%. The Round Table Services Llc holds 1.50 million shares with $21.13M value, up from 1.36M last quarter. New Mtn Fin Corp now has $1.11 billion valuation. The stock increased 0.34% or $0.05 on June 9, reaching $14.65. About shares traded. New Mountain Finance Corp. (NYSE:NMFC) has risen 17.77% since June 12, 2016 and is uptrending. It has outperformed by 1.07% the S&P500.

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The company has market cap of $13.45 million. The Firm primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. It currently has negative earnings. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Among 5 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Apricus Bioscience Inc had 6 analyst reports since August 6, 2015 according to SRatingsIntel. On Friday, November 6 the stock rating was downgraded by TH Capital to “Neutral”. The stock of Apricus Biosciences Inc (NASDAQ:APRI) earned “Outperform” rating by FBR Capital on Friday, November 6. The rating was downgraded by Sterne Agee CRT to “Neutral” on Wednesday, December 9. The firm has “Buy” rating by Ascendiant Capital Markets given on Thursday, August 13. The rating was downgraded by Roth Capital to “Neutral” on Friday, November 6.